help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

The Oncologist, Vol. 12, No. 4, 443-450, April 2007; doi:10.1634/theoncologist.12-4-443
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Target Practice: Lessons From Phase III Trials With Bevacizumab and Vatalan...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Los, M.
Right arrow Articles by Voest, E. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Los, M.
Right arrow Articles by Voest, E. E.

Gastrointestinal Cancer

Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer

Maartje Los, Jeanine M. L. Roodhart, Emile E. Voest

Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

Key Words. Colorectal cancer • Angiogenesis inhibitors • Bevacizumab • Vatalanib

Correspondence: Correspondence: Emile E. Voest, M.D., Ph.D., Department of Medical Oncology F 02 126, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands. Telephone: 31-30-2506265; Fax: 31-30-2523741; email: e.e.voest{at}umcutrecht.nl

Vascular endothelial growth factor (VEGF) is one of the most important factors involved in tumor angiogenesis and has become an important target for anticancer treatment. In 2004, this approach was validated in a randomized, controlled phase III clinical trial. It was shown that the addition of bevacizumab, a humanized monoclonal antibody against VEGF-A, to conventional chemotherapy prolonged survival over chemotherapy alone in patients with metastatic colorectal cancer. In this review, we discuss the results of the clinical trials that have led to the incorporation of antiangiogenic agents into the treatment of patients with advanced colorectal cancer. We limit ourselves to the two agents that have been tested extensively in phase III trials: bevacizumab and vatalanib, a small molecule tyrosine kinase inhibitor against VEGF receptors. In addition, we discuss the adverse effects of bevacizumab and vatalanib and the clinical management of the side effects.

Disclosure of potential conflicts of interest is found at the end of this article.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
E. I. Ager, J. Neo, and C. Christophi
The renin-angiotensin system and malignancy
Carcinogenesis, September 1, 2008; 29(9): 1675 - 1684.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
C. Halin, H. Fahrngruber, J. G. Meingassner, G. Bold, A. Littlewood-Evans, A. Stuetz, and M. Detmar
Inhibition of Chronic and Acute Skin Inflammation by Treatment with a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor
Am. J. Pathol., July 1, 2008; 173(1): 265 - 277.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2007 by AlphaMed Press.